Key Highlights
- First quarter 2026 net loss decreased to $5.51M compared to $8.20M in the prior-year quarter.
- Loss per diluted share narrowed significantly to $(6.95) versus $(57.76) year-over-year.
- Cash position stood at $9.2M at quarter-end, supported by a $10.5M capital raise completed in February.
- ERNA-101 therapy candidate demonstrated complete tumor elimination and 100% sustained survival in preclinical testing combined with PD-1 treatment.
- Company executed 1-for-25 reverse stock consolidation in May and registered $50M shelf offering featuring ATM facility for capital flexibility.
Shares of Ernexa Therapeutics (ERNA) climbed more than 78% on May 11 following the release of first-quarter 2026 financial results. The early-stage cell therapy developer delivered improved financial metrics while providing updates on its therapeutic programs.
Ernexa Therapeutics Inc., ERNA
For the three months ending March 31, 2026, Ernexa recorded a net loss of $5.51 million, representing a meaningful decline from the $8.20 million loss reported during the equivalent period in 2025. This marks a $2.70 million reduction in quarterly losses.
The diluted loss per share metric showed substantial improvement, registering $(6.95) versus $(57.76) in the first quarter of 2025. The prior year’s per-share figure incorporates pre-reverse split calculations, as the company implemented a 1-for-25 stock consolidation effective May 4, 2026.
Quarterly operating expenditures reached $5.6 million. This figure encompasses $1.9 million allocated to research and development activities, $1.6 million in general and administrative overhead, plus a $2.0 million impairment charge related to goodwill.
The company’s cash reserves totaled $9.2 million at quarter close. This balance benefited from a February equity financing that generated roughly $10.5 million in gross capital through the sale of common stock, pre-funded warrants, and performance-based milestone warrants.
Company leadership acknowledged that April 30 cash levels of approximately $8.3 million remain insufficient to fund anticipated operational requirements throughout the coming twelve months.
Addressing this funding requirement, Ernexa registered a $50 million universal shelf offering and established an at-the-market equity distribution program, which management anticipates will provide access to roughly $9.2 million in additional capital.
Lead Program ERNA-101 Delivers Encouraging Preclinical Results
Regarding pipeline development, ERNA-101, the firm’s primary cancer therapy candidate, achieved tumor growth inhibition in animal disease models. When administered alongside PD-1 checkpoint inhibitor therapy, the combination yielded complete tumor regression and 100% extended survival across the preclinical studies conducted.
These findings represent laboratory-stage data — clinical validation in human subjects remains the critical next milestone. Ernexa disclosed completion of a pre-investigational new drug application meeting with regulatory authorities and intends to file an IND submission during the latter portion of 2026, targeting initiation of a Phase I investigator-led clinical trial in the second half of this year.
The organization is simultaneously progressing ERNA-201, an IL-10-expressing induced mesenchymal stem cell platform targeting autoimmune diseases, while actively exploring collaborative partnerships and grant opportunities to fund continued development efforts.
International Growth Initiatives and Regulatory Compliance Measures
Beyond research programs, Ernexa secured admission into a Japanese trade acceleration initiative designed to facilitate commercial entry into the Japanese healthcare market.
The reverse stock consolidation, which resulted in 1,166,333 outstanding common shares as of May 8, 2026, served partially as a regulatory compliance strategy. Management anticipates this structural change will enable the company to restore Nasdaq minimum bid price requirements.
As of the March 31, 2026 reporting date, outstanding common stock totaled 1,166,333 shares on a post-split adjusted basis.
